Avidity Biosciences Retained Earnings (Accumulated Deficit) 2019-2024 | RNA

Avidity Biosciences retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-0.791B, a 54.96% increase year-over-year.

  • Avidity Biosciences retained earnings (accumulated deficit) for 2023 were $-0.571B, a 59.19% increase from 2022.
  • Avidity Biosciences retained earnings (accumulated deficit) for 2022 were $-0.359B, a 94.28% increase from 2021.
  • Avidity Biosciences retained earnings (accumulated deficit) for 2021 were $-0.185B, a 177.35% increase from 2020.

Avidity Biosciences Retained Earnings (Accumulated Deficit) 2019-2024 | RNA

  • Avidity Biosciences retained earnings (accumulated deficit) for 2023 were $-0.571B, a 59.19% increase from 2022.
  • Avidity Biosciences retained earnings (accumulated deficit) for 2022 were $-0.359B, a 94.28% increase from 2021.
  • Avidity Biosciences retained earnings (accumulated deficit) for 2021 were $-0.185B, a 177.35% increase from 2020.